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Frédéric Lioté, Tony Merriman, Sonia Nasi and Alexander So*The 4th workshop of the European Crystal Network
took place recently in Paris. Approximately 40 biomed-
ical scientists took part in this closed meeting, whose
aim was to facilitate scientific exchange and foster col-
laborations between centers involved in research in
crystal-induced inflammation and crystal deposition dis-
eases. Rheumatology was well represented at the meet-
ing, but there were also participants from other medical
disciplines (genetics, epidemiology, nephrology) and
basic scientists with diverse interests (crystallography,
biochemistry, inflammation, physics).
Within the rheumatic diseases, a major focus is gout
and hyperuricemia, but the role of calcium crystals in
disease is also gaining interest. Recent advances in gen-
etics, inflammation research and the biochemical path-
ways that mediate calcium crystal deposition were some
of the highlights of this year’s meeting. New clinical and
therapeutic aspects of hyperuricemia and gout were also
discussed. This report summarizes the subjects that were
presented with reference to gout and hyperuricemia.
Other presentations on the mechanisms of tissue calcifi-
cation and their possible role in osteoarthritis are not
summarized here.Hyperuricemia and gout
What is the normal serum uric acid level?
Thomas Bardin (Paris, France) reviewed the current def-
inition of what the normal level of serum uric acid
(SUA) is based on. The current definition is population
based and is remarkably similar to the solubility thresh-
old of 420 μmol/l (7.0 mg/dl). Interestingly, this SUA
level also predicted incident gout in epidemiological
studies. However, up to 10% of gout patients had SUA
levels between 6.0 and 7.0 mg/dl, suggesting that
monosodium urate (MSU) crystals can also form at
lower concentrations. He suggested that 6.0 mg/dl may
be a more appropriate normal SUA concentration, and* Correspondence: Alexanderkai-lik.so@chuv.ch
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© BioMed Central Ltd.2013this value is also the recommended target level for
urate-lowering therapy. In gout cases there is no reason
to have different normal SUA levels between men and
women, because the phenomenon of crystal formation is
the same.
Proteomic analysis in intercritical gout
Tim Radstake (Nijmegen, the Netherlands) presented data
from ongoing studies on the proteomic analyses of
serum from patients in the Netherlands and New Zealand
with acute and intercritical gout. These studies found that
IL-8 levels were significantly increased in both situations.
A different proteomic profile, which correlated with
S100A8 levels, was observed when patients with high or
low IL-8 levels were compared.
Imaging in the diagnosis of gout
Nicola Dalbeth (Auckland, New Zealand) presented a re-
view on current imaging techniques in gout. Dual-
energy computed tomography scan provided a clear
demonstration of MSU deposits around joints and ten-
dons. Future research should focus on comparison be-
tween the different imaging modalities (ultrasonography
study and dual-energy computed tomography) in early
gout or even in asymptomatic hyperuricemia.
Urate excretion in the general population
Muriel Bochud (Lausanne, Switzerland) reported data
on urinary fractional excretion of uric acid (FEUA) from
COLAUS, a population-based cohort that included 6,000
Caucasian participants, aged 35 to 75 years, in Lausanne.
SUA as well as urinary urate from spot urine samples
were measured in each subject. The results showed that
FEUA is higher in women than in men. There is a clear
negative independent association of FEUA with body
mass index, mainly fat mass, fasting insulin levels, trigly-
ceride levels, γ-glutamyltranspeptidase levels, estimated
glomerular filtration rate (Chronic Kidney Disease Epi-
demiology Collaboration equation), and ultrasensitive
C-reactive protein. These preliminary results highlight
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Fructose loading and urate handling
Tony Merriman (Dunedin, New Zealand) reported the
results of physiological overload of oral fructose loading.
Epidemiological data suggest a relationship between
sugar-sweetened soft drink consumption and gout. In
collaboration with Nicola Dalbeth, he studied whether
genetic variation in SLC2A9, a fructose and urate trans-
porter, influences the acute urate response to a fructose
load. Caucasians without the protective C allele had a
higher increase in serum urate and lower FEUA. No ef-
fect was seen in people of Polynesian ancestry. They
concluded that SLC2A9 might have a greater influence
on the renal response to sugary beverages in Europeans.
Additional results were provided on the effects of a gen-
etic variant for ABCG2, another tubule efflux trans-
porter. Their data showed that the urate-raising variant
of ABCG2 increased FEUA.
Tophus and bone destruction
From the literature and from her own pathological stud-
ies, Nicola Dalbeth (Auckland, New Zealand) described
the pathology of a tophus. MSU crystals are surrounded
by a cellular corona of inflammatory and resident mac-
rophages, including multinucleated giant cells that have
features of osteoclasts. Indeed, in vitro experiments
demonstrated direct stimulatory effects of MSU crystals
on osteoclasts, and, by contrast, inhibitory effects on
osteoblasts.
Adrenocorticotropic hormone as a treatment of acute
gout
Fernando Perez-Ruiz (Vizcaya, Spain) reported on the
efficacy of adrenocorticotropic hormone as a treatment
for gout flares based on open and short-term studies.
The anti-inflammatory effects of adrenocorticotropic
hormone might rely on steroid effects and on peripheral
action through activation of the melanocortin type 3 re-
ceptor expressed on monocyte–macrophages (via inhib-
ition of cell migration mediated by cytokine and
adhesion molecule expression and the ability to interfere
with cell signaling pathways). Current randomized trials
comparing adrenocorticotropic hormone and steroid
depot injection in patients with acute gout are ongoing
in Spain.
Cellular effects of crystals
P2X7 receptor and inflammasome activation
Francesco Di Virgilio (Ferrara, Italy) reviewed the biology
of the P2X7 receptor. The P2X7 receptor binds extracellu-
lar ATP and is a potent activator of the NLRP1 and NLRP3
inflammasomes. Potential mechanisms include changes inthe intracellular K+ and Ca2+ concentrations. Pathogen-
associated molecular patterns and danger-associated
molecular patterns were also shown to interact directly
with scaffold proteins of the inflammasomes and initiate
their activation. Finally, a body of evidence shows that
the inflammasomes may be involved in the regulation of
cell growth and differentiation.
Signal transduction in basic calcium phosphate crystal-
induced inflammation
Geraldine McCarthy (Dublin, Ireland) reviewed the
pathologies associated with basic calcium phosphate
deposition. In vitro, basic calcium phosphate promotes
cytokine and matrix metalloproteinase production and
drives IL-1β and IL-18 production following NLRP3
inflammasome activation. Dr McCarthy demonstrated a
role for Syk and phosphoinositide-3 kinases and charac-
terized events downstream of Syk activation to identify
novel targets for treatment of basic calcium phosphate-
related arthritis. Basic calcium phosphate also induced
S100A8 release, and led to the expression of pro-IL-1β
and pro-IL-18. These results suggest that Syk may be a
potential therapeutic target in basic calcium phosphate-
related disorders.
α-antitrypsin in gout
Leo Joosten (Nijmegen, the Netherlands) discussed
inflammasome-independent mechanisms of IL-1β by
MSU crystals in mice and showed that neutrophil serine
proteinases such as PR3 were implicated. α1-antitrypsin
(AAT) is an abundant serine proteinase inhibitor and
is able to inhibit PR3. The effect on MSU-induced in-
flammation was explored using human AAT-transgenic
mice and a recombinant AAT-Fc fusion protein. AAT-
transgenic mice were protected against joint inflamma-
tion following intra-articular injection of MSU with free
fatty acids, and treatment with AAT-Fc fusion protein
suppressed joint swelling and local cytokine production
as effectively as a high dose of IL-1Rα (10 mg/mouse).
AAT-Fc treatment was effective up to 48 hours before
induction of gouty arthritis, indicating a long half-life for
this compound. These data indicate that AAT-Fc may be
a novel anti-inflammatory therapy for patients suffering
from gout.
Genetics
Genetics of serum urate
Anne Köttgen (Freiburg, Germany) presented 18 new
genetic variants associated with serum urate levels in a
genome-wide association scan performed by the Global
Urate Genetics Consortium involving a meta-analysis
of 48 studies (>110,000 European subjects). These vari-
ants also increased gout risk. The new genetic variants
clustered into glycolysis and inhibin–activin signaling
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porters were discovered to add to the previously identi-
fied transporters (for example, SLC2A9 and ABCG2).
Dr Köttgen hypothesized that the glycolysis genes could
increase lactate levels and influence renal excretion of
uric acid. How the inhibin–activin genes could influence
urate levels is not clear because they encompass a wide
range of molecular pathways.
Heritability of gout
Dr Chang-Fu Kuo (Nottingham, UK) described the use
of the National Health Insurance Research Database of
Taiwan to estimate heritability of gout. This database in-
cludes demographic and phenotypic information from
>98% of the Taiwanese population (23.03 million individ-
uals in 2010) and genealogical data, from which 16.8
million primary relative pairs were identified. Gout was
defined using the ICD9 code and treatment associated
with gout, with the overall prevalence of gout being
4.62% (7.07% in males and 2.15% in females). Heritability
was estimated under a polygenic model with environ-
mental effects estimated using spouses. The estimated
heritability of gout was 33% in males and 17% in fe-
males. Dr Kuo pointed out that the model used would
provide a conservative estimate of heritability compared
with twin studies.
Relationship between urate and renal function
Tony Merriman (Dunedin, New Zealand) presented data
on increased serum urate predicting poor renal function
independent of other measured risk factors. However,
whether urate per se is detrimental to renal function re-
mains unresolved. The use of Mendelian randomization
that uses genetic variants to test for a causal role of
urate on renal function was described. Data from the
Atherosclerosis Risk in Communities and Framingham
Heart studies were used and a uric acid transporter gen-
etic risk score was employed as the instrumental variable
to test for a causal role of urate in renal function. Over-
all, an increased genetic risk score was associated with
improved renal function in men but not in women.
Genetic determinants of urate excretion
Murielle Bochud (Lausanne, Switzerland) described the
SKIPOGH study, which aims to disentangle the genetic
determinants contributing to renal and hypertensive
phenotypes. This study contains 856 parent–offspring
pairs and 414 sibling–sibling pairs, all of which have
comprehensive renal phenotype data. Heritability esti-
mates of serum urate, FEUA, 24-hour uric acid clearance
and urinary urate clearance were 0.42, 0.45, 0.43 and
0.17, respectively. Good phenotype ascertainment is very
important in this kind of study; for example, in a
Seychelles study the heritability of blood pressure wasestimated as ~10% based on one measure, as ~20%
based on five measures and as ~40% based on 10
measures.
Role of SLC2A9 gene expression in hyperuricemia and
gout
Philip Riches (Edinburgh, UK) reviewed the currently
understood role of the renal uric acid transporter
SLC2A9 (GLUT9) in the proximal renal tubule. Genetic
variants in SLC2A9 are strongly associated with serum
urate levels, explaining 3.5% of phenotypic variance.
SLC2A9 exists as two isoforms – a full length isoform,
and an isoform missing the N-terminal 28 residues. Ex-
pression of the short form (on the apical membrane)
correlates with the urate level, with the full-length iso-
form on the basolateral membrane acting as a dominant
mediator of uric acid exchange. Dr Riches presented
data showing differential renal expression of distinct
SLC2A9 genetic variants, with evidence for an internal
promoter. SLC2A9 is also expressed in synovial tissue.
Eurogout
Eurogout is a European Gout Genetics Consortium,
established under the aegis of the European Crystal Net-
work in 2010 for the recruitment of a very large, well-
ascertained gout sample set for use in genome-wide
genetic studies. Progress was updated – 1,171 cases have
been recruited.
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